OncLive TV

Evan Y. Yu, MD, discusses new data and continuing conversations regarding the use of PARP inhibitors and targeted radioligand therapies in prostate cancer.

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.

Michael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.

Tycel Phillips, MD, MPH, discusses how to approach selecting BTK inhibitors for patients with mantle cell lymphoma and treatment decisions following disease progression on a BTK inhibitor.

Priyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.

Mansi Dalal, MD, discusses findings from a study investigating graft failure risk factors in pediatric patients receiving allogeneic hematopoietic stem cell transplant for non-malignant disorders.

Jordan B. Milner, MD, discusses findings from a study evaluating the use of hematopoietic stem cell transplant up front or as salvage therapy after unsuccessful immunosuppressive therapy in pediatric patients with severe aplastic anemia.

Rima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.

Andre H. Goy, MD, discusses the appropriate monitoring and management of patients with mantle cell lymphoma who display genetic abnormalities but are not considered to be high risk.

James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.

Raajit K. Rampal, MD, PhD, discusses how the role of JAK inhibitors will continue to evolve in the treatment of patients with myelofibrosis.

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

Paul G. Richardson, MD, discusses the impact of combining proteasome inhibitors and monoclonal antibodies in multiple myeloma.

Andrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.

Jimmy Hwang, MD, discusses currently available first-line treatment options in hepatocellular carcinoma, and areas of continued unmet need in this space.

Andre H. Goy, MD, discusses differentiating between disease presentations in mantle cell lymphoma.

Jeremie Calais, MD, MSc, discusses the role of prostate-specific membrane antigen-PET imaging in metastatic-castrate resistant prostate cancer, and touches on the importance of integrating PSMA-PET imaging into community settings for clinical practice.

Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.

Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.

Nathalie McDowell Johnson, MD, FACS, discusses the importance of diverse representation in breast cancer clinical trials.

Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Nita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.

John Ligon, MD, discusses findings from a study investigating the use of mediports to deliver CAR T-cell therapy in patients at Pediatric Real-World CAR Consortium medical centers.

Nirav N. Shah, MD, discusses findings from a preplanned interim futility analysis of the single-arm phase 2 DALY II USA trial in patients with relapsed/refractory diffuse large B-cell lymphoma.

John Mascarenhas, MD, discusses the benefit of fedratinib for patients with myelofibrosis.